快速气流排出法清除声门下分泌物预防呼吸机相关性肺炎:随机对照研究
本研究为单中心、前瞻性随机对照试验,在首都医科大学附属北京朝阳医院呼吸ICU开展,纳入气管插管允许引流声门下分泌物的患者241例,随机分为RFEM组(n=120)与SSD组(n=121),主要终点为VAP发生率,采用非劣效性检验。RFEM组11例(9.17%)发生VAP,SSD组13例(10.74%),差异为-1.59(95%CI -9.20至6.03),95%CI上限未超过预设非劣效界值10%,判定RFEM不劣于SSD。两组机械通气时间、ICU死亡率、ICU住院时间及费用均无统计学显著差异;RFEM组未发生意外拔管或操作相关气压伤,拔管后喉水肿与再插管发生率两组相似。作者认为RFEM有效且安全,可作为呼吸ICU患者的一线替代方法。
要点
- 在呼吸ICU气管插管患者中,RFEM组VAP发生率9.17%(11/120)vs SSD组10.74%(13/121),差异-1.59(95%CI -9.20至6.03),95%CI上限未超过预设非劣效界值10%,RFEM不劣于SSD。
- RFEM组未发生意外拔管或操作相关气压伤,拔管后喉水肿和再插管发生率与SSD组相似。
- 两组机械通气时间、ICU死亡率、ICU住院时间及费用均无统计学显著差异。
- 作者认为RFEM有效且安全,可作为呼吸ICU患者的一线替代方法。
适用人群与场景
- 呼吸ICU中气管插管、且气管导管允许引流声门下分泌物的患者(n=241)。
诊断标准与关键阈值
- 非劣效界值预设为10%,以VAP发生率95%CI上限不超过10%判定非劣效。
研究设计与关键结果
- 单中心、前瞻性随机对照试验,在呼吸ICU开展,纳入241例气管插管允许引流声门下分泌物的患者,随机分为RFEM组(n=120)与SSD组(n=121)。
- 主要终点VAP发生率:RFEM组9.17%(11/120)vs SSD组10.74%(13/121),差异-1.59(95%CI -9.20至6.03),95%CI上限未超过预设非劣效界值10%,RFEM不劣于SSD。
- 机械通气时间、ICU死亡率、ICU住院时间及费用两组无统计学显著差异。
- 安全性:RFEM组未发生意外拔管或操作相关气压伤;拔管后喉水肿和再插管发生率两组相似。
证据类型、等级与局限
- 证据类型:单中心、前瞻性随机对照试验。
- 试验注册于ClinicalTrials.gov(注册号NCT02032849),注册时间为2014年1月。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为RFEM有效且安全,在VAP发生率方面不劣于SSD,可作为呼吸ICU患者的一线替代方法。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Following endotracheal intubation, clearing secretions above the endotracheal tube cuff decreases the incidence of ventilator-associated pneumonia (VAP); therefore, subglottic secretion drainage (SSD) is widely advocated. Our group developed a novel technique to remove the subglottic secretions, the rapid-flow expulsion maneuver (RFEM). The objective of this study was to explore the effectiveness and safety of RFEM compared with SSD.
METHODS: This study was a single-center, prospective, randomized and controlled trial, conducted at Respiratory Intensive Care Unit (ICU) of Beijing Chao-Yang Hospital, a university-affiliated tertiary hospital. The primary outcome was the incidence of VAP, assessed for non-inferiority.
RESULTS: Patients with an endotracheal tube allowing drainage of subglottic secretions (n = 241) were randomly assigned to either the RFEM group (n = 120) or SSD group (n = 121). Eleven patients (9.17%) in the RFEM group and 13 (10.74%) in the SSD group developed VAP (difference, - 1.59; 95% confidence interval [CI] [- 9.20 6.03]), as the upper limit of 95% CI was not greater than the pre-defined non-inferiority limit (10%), RFEM was declared non-inferior to SSD. There were no statistically significant differences in the duration of mechanical ventilation, ICU mortality, or ICU length of stay and costs between groups. In terms of safety, no accidental extubation or maneuver-related barotrauma occurred in the RFEM group. The incidence of post-extubation laryngeal edema and reintubation was similar in both groups.
CONCLUSIONS: RFEM is effective and safe, with non-inferiority compared to SSD in terms of the incidence of VAP. RFEM could be an alternative method in first-line treatment of respiratory ICU patients. Trial registration This study has been registered on ClinicalTrials.gov (Registration Number: NCT02032849, https://clinicaltrials.gov/ct2/show/NCT02032849 ); registered on January 2014.
参考来源
- Li Y, Yuan X, Sun B, et al. Rapid-flow expulsion maneuver in subglottic secretion clearance to prevent ventilator-associated pneumonia: a randomized controlled study. Ann Intensive Care. 2021. PMID: 34165661. doi:10.1186/s13613-021-00887-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。